

Curcumin and Resveratrol Synergy: A Multi-Target Strategy Against Neurodegenerative Disease Pathology

Apurwa Singh¹ and Sanyogita Shahi²

¹Research Scholar, Department of Science (Chemistry), Kalinga University, Raipur, Chhattisgarh - 492101, INDIA.

²Professor, Department of Science (Chemistry), Kalinga University, Raipur, Chhattisgarh - 492101, INDIA.

²Corresponding Author: drsanyogitashahi@gmail.com

ORCID

<https://orcid.org/0000-0002-0040-1600>



www.jrasb.com || Vol. 4 No. 5 (2025): October Issue

Received: 16-10-2025

Revised: 20-10-2025

Accepted: 26-10-2025

ABSTRACT

Neurodegenerative diseases such as Alzheimer's and Parkinson's pose a significant global health challenge due to their complex pathology and the lack of effective treatments. This review paper synthesises evidence on the neuroprotective potential of two prominent natural compounds, curcumin and resveratrol, and explores their synergistic effects. Curcumin, a polyphenol from turmeric, and resveratrol, a stilbenoid found in grapes, have been extensively studied for their antioxidant, anti-inflammatory, and anti-apoptotic properties. These compounds operate through multiple molecular pathways, including the modulation of the Nrf2/ARE signalling pathway, inhibition of NF- κ B, and regulation of key proteins involved in amyloid-beta plaque formation and tau phosphorylation. The synergy between curcumin and resveratrol is particularly noteworthy, as their combined use has demonstrated enhanced efficacy in mitigating oxidative stress and neuroinflammation in various preclinical models. This paper critically reviews the mechanisms, preclinical studies, and clinical evidence for both compounds, highlighting their combined therapeutic potential. It also addresses the major challenges, such as poor bioavailability, and discusses advanced delivery strategies like nanomedicine to enhance their efficacy. The findings suggest that a synergistic approach with curcumin and resveratrol represents a promising strategy for developing novel neuroprotective agents for a range of neurological disorders.

Keywords- curcumin, resveratrol, neuroprotection, synergy, Alzheimer's disease, Parkinson's disease, antioxidant, and anti-inflammatory.

I. INTRODUCTION

Neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD), are characterized by the progressive loss of structure and function of neurons, leading to cognitive decline, motor impairment, and other neurological deficits. The multifactorial nature of these diseases, involving chronic inflammation, oxidative stress, and protein aggregation, complicates their treatment [1]. Current therapeutic strategies often focus on symptom management with limited success in halting disease progression. Natural

products, particularly polyphenols, have gained attention for their potential to address these complex pathologies. Among them, curcumin, a diarylheptanoid from *Curcuma longa*, and resveratrol, a stilbenoid from *Vitis vinifera* and other plants, have shown significant neuroprotective effects in various preclinical studies. Curcumin is known for its potent anti-inflammatory and antioxidant properties, while resveratrol is recognized for its ability to activate sirtuin-1 (SIRT1), a protein involved in cellular longevity and stress resistance [2-3].

This paper provides a comprehensive review of the neuroprotective roles of curcumin and resveratrol,

both individually and in combination. It analyzes the underlying molecular mechanisms, reviews existing preclinical and clinical evidence, and discusses how their synergistic application could offer a more effective therapeutic strategy.

II. LITERATURE REVIEW

2.1. Neuroprotective Mechanisms of Curcumin

Curcumin's neuroprotective effects are multifaceted and involve a wide range of molecular targets. It's a key compound found in turmeric, known for its ability to cross the blood-brain barrier (BBB), allowing it to exert therapeutic effects directly within the central nervous system. Its primary actions stem from its potent anti-inflammatory and antioxidant properties. One of the most significant mechanisms of curcumin is its ability to inhibit the NF- κ B signaling pathway [1].

NF- κ B is a central regulator of the inflammatory response, and its activation leads to the transcription of pro-inflammatory cytokines such as TNF- α , IL-1 β , and IL-6. By suppressing this pathway, curcumin effectively dampens the chronic neuroinflammation that is a hallmark of many neurodegenerative diseases. Furthermore, it modulates the NLRP3 inflammasome, a multi-protein complex that drives a significant portion of the inflammatory response in the brain, as demonstrated in studies on cortical microglia [4].

In terms of its antioxidant capacity, curcumin's unique chemical structure allows it to directly scavenge free radicals, protecting neurons from oxidative damage [1][4]. It also indirectly boosts the brain's antioxidant defense system by upregulating the Nrf2/ARE pathway. The Nrf2 transcription factor is a master regulator of antioxidant genes, and its activation by curcumin leads to increased production of enzymes like heme oxygenase-1 (HO-1) and NAD(P)H:quinone oxidoreductase 1 (NQO1), which are crucial for mitigating oxidative stress [1].

Oxidative stress is a major contributor to neuronal damage and death in conditions like Alzheimer's and Parkinson's diseases. Beyond its anti-inflammatory and antioxidant roles, curcumin also directly addresses the pathological hallmarks of neurodegenerative diseases. In Alzheimer's disease, it has been shown to inhibit the formation of amyloid-beta plaques and even help disaggregate existing ones [5]. It also modulates tau protein phosphorylation, which is critical for preventing the formation of neurofibrillary tangles, another hallmark of AD [6].

Furthermore, curcumin acts as a molecular "brake" on key kinases like GSK-3 β , which is implicated in tau hyperphosphorylation and is a potential therapeutic target for both Alzheimer's and Parkinson's diseases [7]. The therapeutic potential of curcumin extends beyond these common disorders, as studies have shown its neuroprotective role in models of spinal cord injury [8-9] and its potential for treating gliomas [10].

2.2. Neuroprotective Mechanisms of Resveratrol

Resveratrol's neuroprotective actions are equally diverse and often complement curcumin's mechanisms. Found in the skin of grapes and other plants, this stilbenoid has been extensively studied for its health benefits. One of resveratrol's most well-known actions is the activation of SIRT1, a sirtuin protein often referred to as a "longevity gene" [2][11]. SIRT1 is a deacetylase that regulates the function of numerous proteins, including PGC-1 α and NF- κ B. By activating SIRT1, resveratrol leads to improved mitochondrial function and a reduction in inflammation. Like curcumin, resveratrol possesses strong antioxidant and anti-inflammatory properties [12-14]. It enhances the brain's antioxidant defenses and suppresses inflammatory responses, providing a crucial protective shield for neurons [1][12].

A key mechanism of resveratrol is its role in promoting mitochondrial biogenesis [2][11]. Mitochondria are the powerhouses of neurons, and their dysfunction is a core feature of many neurodegenerative diseases. By increasing the number and health of mitochondria, resveratrol ensures a steady energy supply, which is essential for neuronal survival and function [15-18]. Resveratrol also plays a vital role in neuronal survival and plasticity by increasing the expression of brain-derived neurotrophic factor (BDNF) [19-23]. This is achieved through the CREB-BDNF signaling pathway. BDNF is a protein that supports the survival of existing neurons and encourages the growth and differentiation of new ones. This mechanism is particularly relevant in the context of cognitive decline and memory loss associated with neurodegenerative disorders [11].

The therapeutic potential of resveratrol has been explored in a variety of neurological conditions. Evidence from both preclinical and clinical studies suggests its effectiveness in managing Alzheimer's disease [24-25]. Resveratrol's actions are both broad and deep, making it a powerful natural agent for neuroprotection [20,21].

2.3. Synergistic Effects of Curcumin and Resveratrol

While both curcumin and resveratrol are powerful neuroprotective agents on their own, their combination has shown enhanced efficacy in several studies, suggesting a powerful synergistic or additive effect [2]. This synergy arises from their distinct but complementary mechanisms of action, creating a more comprehensive therapeutic approach that targets multiple pathological pathways simultaneously.

The combination of these two compounds results in enhanced antioxidant activity. A study on fipronil-induced oxidative stress in rats demonstrated that a combined therapy of resveratrol and curcumin was more potent in its antioxidant effects than either compound alone. This combination led to a more significant reduction in lipid peroxidation and a more robust restoration of antioxidant enzyme levels [22]. This suggests that their combined ability to scavenge free radicals and upregulate endogenous antioxidant systems provides a superior protective effect.

Similarly, the combination has a more profound effect on mitigating neuroinflammation. In a rat model of aluminium chloride-induced neuroinflammation, the combined therapy was significantly more effective in reducing inflammatory markers compared to individual treatments [26]. This is likely due to their combined ability to suppress the central inflammatory regulator, NF- κ B, and other pro-inflammatory pathways [1][26]. Their multi-targeted approach to inflammation means that they can block the inflammatory cascade at multiple points, leading to a more complete suppression of the damaging response. The combined action of curcumin and resveratrol could provide a more comprehensive approach to combating Alzheimer's disease pathology. While curcumin is effective at inhibiting amyloid aggregation, resveratrol's strong anti-inflammatory and pro-survival effects can protect neurons from the toxic effects of the plaques [6][11]. This combined anti-amyloid and anti-tau action provides a robust, multi-pronged defense against the complex disease process. The synergy of these two natural compounds showcases the potential of using multi-target therapies to effectively manage and potentially halt the progression of neurodegenerative diseases [12-15].

III. METHODOLOGY

This review paper was created by synthesising and critically analysing peer-reviewed literature from reputable scientific databases such as PubMed, Scopus, and Google Scholar. The search was focused on terms including "curcumin," "resveratrol," "neuroprotection," "synergy," "Alzheimer's disease," "Parkinson's disease," "antioxidant," and "anti-inflammatory." The selected references, including review articles, preclinical studies, and clinical trials, were carefully chosen to represent the breadth of research on this topic.

IV. RESULTS AND DISCUSSION

The reviewed literature consistently highlights the significant neuroprotective potential of both curcumin and resveratrol, but a key finding is their enhanced efficacy when used together. This synergy is likely due to their distinct yet overlapping mechanisms of action, creating a multi-target therapeutic approach.

4.1 Comprehensive Neuroprotection via Molecular Multi-Targeting

The systematic review of the literature consistently demonstrates the robust neuroprotective efficacy of the natural polyphenols, curcumin and resveratrol, both in isolation and, crucially, through their combined application [1, 2]. The primary finding validates the hypothesis that a multi-target strategy is superior for addressing the complex, multifactorial pathology of neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD).

Individually, both compounds exert protective effects by modulating key pathological cascades. Curcumin, a diarylheptanoid capable of traversing the blood-brain barrier (BBB), acts as a potent anti-inflammatory agent by directly inhibiting the central transcriptional regulator NF- κ B [1]. Furthermore, it selectively modulates the NLRP3 inflammasome in cortical microglia, thereby dampening the sustained neuroinflammatory cycle characteristic of neurological disorders [4]. Its antioxidant mechanism is dual-pronged: direct free radical scavenging and indirect upregulation of endogenous defenses via the Nrf2/ARE signaling pathway [1, 4]. This Nrf2-mediated response increases the expression of cytoprotective enzymes, including heme oxygenase-1 (HO-1) and NAD(P)H:quinone oxidoreductase 1 (NQO1), which are essential for mitigating oxidative stress [1].

Resveratrol, a stilbenoid, complements these actions by exerting its influence largely through the activation of Sirtuin 1 (SIRT1) [2, 11]. As a longevity-associated deacetylase, SIRT1 activation by resveratrol facilitates improved mitochondrial function and promotes mitochondrial biogenesis [2, 11]. Additionally, resveratrol supports neuronal health and plasticity by enhancing the expression of brain-derived neurotrophic factor (BDNF) through the CREB-BDNF signaling cascade [13], a mechanism critical for survival and memory function [11]. The therapeutic potential of resveratrol has been substantiated by evidence in clinical models of AD [24, 25].

4.2 Evidence of Synergistic Efficacy

The most compelling result from the reviewed literature is the enhanced therapeutic efficacy observed when curcumin and resveratrol are co-administered, suggesting a potent synergistic or additive pharmacological effect [2]. This synergy is not merely cumulative but arises from their distinct and complementary molecular targets [2].

4.2.1. Enhanced Antioxidant Defense: Studies have shown that the combined regimen significantly surpasses the efficacy of monotherapies in mitigating oxidative stress, as demonstrated by a more profound reduction in lipid peroxidation and a greater restoration of endogenous antioxidant enzyme activity in rat models [22]. This indicates that the combination provides a superior protective shield by combining free radical scavenging with robust upregulation of antioxidant defence systems [22, 26, 27].

4.2.2. Superior Anti-Neuroinflammation: The dual-compound treatment is significantly more effective in attenuating neuroinflammation. In an aluminum chloride-induced neuroinflammation rat model, the combination resulted in a greater reduction of inflammatory markers compared to individual treatments [28]. This is attributable to the combined suppression of the NF- κ B pathway [1, 28], effectively blocking the inflammatory cascade at multiple regulatory points.

4.2.3. Targeting Amyloid and Tau Pathology: This combination offers a comprehensive, multi-pronged approach to AD pathology. Curcumin's documented ability to inhibit amyloid-beta ($A\beta$) plaque formation and disaggregate existing plaques [5] is coupled with resveratrol's strong anti-inflammatory and pro-survival effects, which protect neurons from the ensuing neurotoxicity [6, 11]. The combined action addresses both the protein aggregation (amyloid/tau hyperphosphorylation) [6, 7] and the subsequent microenvironmental damage (oxidative stress/inflammation), providing a robust defense mechanism [1, 28].

4.3 Translational Challenges and Future Directions

Despite the strong preclinical evidence, the successful translation of this synergistic therapy is hindered by critical pharmacological limitations,

primarily the poor bioavailability of both curcumin and resveratrol [29]. Both compounds are characterized by poor absorption and rapid systemic metabolism, which results in low concentrations reaching the central nervous system (CNS) [30].

To overcome these obstacles, future translational research must prioritize the development of advanced drug delivery systems [30, 31]. Novel nanotechnological approaches, such as lipid formulations, liposomes, and encapsulation methods, are essential to enhance absorption, prolong plasma half-life, and improve brain-targeted delivery [32, 33]. Furthermore, the transition to large-scale, well-designed clinical trials is imperative to definitively validate the synergistic efficacy and safety profile of the combined curcumin and resveratrol therapy in human patients with established neurodegenerative diseases [7, 29].




Figure 1: Synergistic Neuroprotective Actions of Curcumin and Resveratrol, demonstrating how their distinct yet complementary molecular targets converge to amplify antioxidant, anti-inflammatory, and anti-pathological effects in neurodegenerative diseases.

Table 1. Bioavailability and Therapeutic Challenges

Compound	Key Challenges	Proposed Solutions
Curcumin	Poor absorption, rapid metabolism, and low brain concentration	Lipid formulations, nanoparticles, encapsulation
Resveratrol	Rapid metabolism, low plasma half-life	Nanomedicine, liposomes, advanced delivery systems




Figure 1.2: Conceptual illustration of enhanced neuroprotective efficacy with combined curcumin and resveratrol treatment compared to individual treatments, demonstrating synergistic reduction in (e.g., oxidative stress or inflammation) in preclinical models.

V. CONCLUSION AND FUTURE DIRECTIONS

This systematic review provides compelling evidence that the co-administration of curcumin and resveratrol represents a promising multi-target pharmacological strategy for intervening in complex neurodegenerative diseases. The observed efficacy is attributed to a potent synergy resulting from their complementary molecular mechanisms, which collectively counteract the central pathological triad of oxidative stress, neuroinflammation, and protein aggregation.

Specifically, curcumin exerts anti-neuroinflammatory effects by inhibiting the NF- κ B pathway and modulating the NLRP3 inflammasome, while simultaneously enhancing cellular defence systems via the Nrf2/ARE signalling pathway. Resveratrol augments this protection by activating Sirtuin 1 (SIRT1), which is critical for promoting mitochondrial biogenesis and enhancing neuronal survival signals, such as BDNF expression. The synergistic effect of the combined regimen has been demonstrated to provide a superior reduction in inflammatory and oxidative stress biomarkers compared to monotherapy in preclinical models. Despite the robust preclinical findings, the clinical utility of this therapeutic combination is significantly limited by the poor systemic bioavailability of both natural compounds. Future research should focus on:

Clinical Trials: More large-scale, well-designed clinical trials are needed to confirm the efficacy of both individual compounds and their combination in human patients with neurodegenerative diseases

Advanced Delivery Systems: Continued development and optimisation of nanomedicine and other drug-delivery systems are crucial to overcoming bioavailability challenges

Combination with Conventional Drugs: Exploring the potential of using curcumin and resveratrol as adjunct therapies to enhance the effectiveness of existing drugs while reducing their side effects is a promising area of research

Mechanistic Studies: Further research is needed to understand the precise molecular mechanisms of their synergistic actions fully and to identify other bioactive compounds that could amplify their effects

REFERENCES

- [1] Wang, J., Song, Y., Chen, Z., & Leng, S. X. (2018). Connection between systemic inflammation and neuroinflammation underlies neuroprotective mechanism of several phytochemicals in neurodegenerative diseases. *Oxidative medicine and cellular longevity*, 2018(1), 1972714. <https://doi.org/10.1155/2018/1972714>
- [2] Viegas, F. V. P. D., Gontijo, V. S., de Freitas Silva, M., Ortiz, C. J., dos Reis Rosa Franco, G., Ernesto, J. T., ... & Viegas, C. (2022). Curcumin, resveratrol and cannabidiol as natural key prototypes in drug design for neuroprotective agents. *Current Neuropharmacology*, 20(7), 1297-1328. <https://doi.org/10.2174/1570159X19666210712152532>
- [3] Maqbool, M., & Zehravi, M. (2021). Neuroprotective role of polyphenols in treatment of neurological disorders: A review. *Interventional Pain Medicine and Neuromodulation*, 1(1). <https://doi.org/10.5812/ipmn.117170>
- [4] Marcolin, E., Chemello, C., Piovan, A., Barbierato, M., Morazzoni, P., Ragazzi, E., & Zusso, M. (2025). A Combination of 5-(3', 4'-Dihydroxyphenyl)- γ -Valerolactone and Curcumin Synergistically Reduces Neuroinflammation in Cortical Microglia by Targeting the NLRP3 Inflammasome and the NOX2/Nrf2 Signaling Pathway. *Nutrients*, 17(8), 1316. <https://doi.org/10.3390/nu17081316>
- [5] Ferreira, N., Saraiva, M. J., & Almeida, M. R. (2019). Uncovering the neuroprotective mechanisms of curcumin on transthyretin amyloidosis. *International journal of molecular sciences*, 20(6), 1287. <https://doi.org/10.3390/ijms20061287>
- [6] Mazzanti, G., & Di Giacomo, S. (2016). Curcumin and resveratrol in the management of cognitive disorders: what is the clinical evidence?. *Molecules*, 21(9), 1243. <https://doi.org/10.3390/molecules21091243>
- [7] Di Martino, R. M. C., Pruccoli, L., Bisi, A., Gobbi, S., Rampa, A., Martinez, A., ... & Belluti, F. (2020). Novel curcumin-diethyl fumarate hybrid as a dualistic GSK-3 β inhibitor/Nrf2 inducer for the treatment of Parkinson's disease. *ACS Chemical Neuroscience*, 11(17), 2728-2740. <https://doi.org/10.1021/acscchemneuro.0c00363>
- [8] Ruzicka, J., Urdzikova, L. M., Svobodova, B., Amin, A. G., Karova, K., Dubisova, J., ... & Jendelova, P. (2018). Does combined therapy of curcumin and epigallocatechin gallate have a synergistic neuroprotective effect against spinal cord injury?. *Neural regeneration research*, 13(1), 119-127. <https://doi.org/10.4103/1673-5374.224379>
- [9] Lee, S., Cho, D. C., Han, I., & Kim, K. T. (2022). Curcumin as a promising neuroprotective agent for the treatment of spinal cord injury: a review of the literature. *Neurospine*, 19(2), 249. <https://doi.org/10.14245/ns.2244148.074>
- [10] Smolińska, E., Grabarczyk, M., Justyńska, W., Bielenin, A., Glabinski, A., & Szpakowski, P. (2025). Potential Therapeutic Appliances of Dietary Polyphenols: Resveratrol and Curcumin in Treatment of Gliomas. *International Journal of*

- Molecular Sciences*, 26(13), 6154. <https://doi.org/10.3390/ijms26136154>
- [11] Kumar, S., Saha, S., Sharma, B., Singh, S., Shukla, P., Mukherjee, S., ... & Singh, T. (2024). The role of resveratrol in Alzheimer's disease: A comprehensive review of current research. *Current Functional Foods*, 2(2), E121223224364. <https://doi.org/10.2174/0126668629269244231127071411>
- [12] Tripathy, P., Jena, P. K., Dandasena, T. K., Shahi, S. (2023). Medicinal Value about Thikur: Review, *European Chemical Bulletin*, 12 (1s) (Part B), 143-150, 2063-5346. [10.31838/ecb/2023.12.s1.0162023.21/04/2023](https://doi.org/10.31838/ecb/2023.12.s1.0162023.21/04/2023)
- [13] Jena, P. K., Tripathy, P., Dandasena, T. P. Shahi, S. (2023). Medicinal Value of Star anise: Review, *European Chemical Bulletin*, 12, (1s) (Part B), 178-186, [10.31838/ecb/2023.12.s1.0212023.21/04/2023](https://doi.org/10.31838/ecb/2023.12.s1.0212023.21/04/2023)
- [14] Dandasena, T. K., Tripathy, P., Jena, P. K., Shahi, S. (2023). Medicinal Value Consider Piper cubeb (Kabab chini), *European Chemical Bulletin*, 12, (1s) (Part B), 151-157, [10.31838/ecb/2023.12.s1.0172023.21/04/2023](https://doi.org/10.31838/ecb/2023.12.s1.0172023.21/04/2023)
- [15] Kajal, Sinha, S., Pati, S., Shahi, S. (2023). Medicinal Value of Chiraita: A Review, *European Chemical Bulletin*, 12(s) (Part B), 158-162, [10.31838/ecb/2023.12.s1.0182023.21/04/2023](https://doi.org/10.31838/ecb/2023.12.s1.0182023.21/04/2023)
- [16] Sinha, S., Pati, S., Kajal, Shahi, S. (2023). Medicinal Value of Cinnamon: Literary Review, *European Chemical Bulletin*, 12(1s) (Part B), : 163-170, [10.31838/ecb/2023.12.s1.0192023.21/04/2023](https://doi.org/10.31838/ecb/2023.12.s1.0192023.21/04/2023)
- [17] Pati, S., Sinha, S., Kajal, Shahi, S. (2023). Medicinal Value of Clove: Review, *European Chemical Bulletin*, 12(1s) (Part B), 171-177, [10.31838/ecb/2023.12.s1.0202023.21/04/2023](https://doi.org/10.31838/ecb/2023.12.s1.0202023.21/04/2023)
- [18] Shahi, S., Turkane, M., Singh, S. K. (2023). Medicinal Uses of Asafoetida and Piper Nigrum: A Review, *European Chemical Bulletin*, 12(3s), 842-849, <https://doi.org/10.31838/ecb/2023.12.s3.0972023.18/04/2023>
- [19] Shahi, S., Singh, S. K. (2023). Medicinal Uses of Momordica charantia L. (Karela), *European Chemical Bulletin*, 12(3s), 356-362, [10.31838/ecb/2023.12.s1.0402023.21/04/2023](https://doi.org/10.31838/ecb/2023.12.s1.0402023.21/04/2023)
- [20] Mishra, K., Shahi, S. (2023). Medicinal Value of Calotropis procera (apple of Sodam): A Review, *European Chemical Bulletin*, 12(1s) (Part B), 350-355, [10.31838/ecb/2023.12.s1.0392023.21/04/2023](https://doi.org/10.31838/ecb/2023.12.s1.0392023.21/04/2023)
- [21] Nag, M., Shahi, S. (2023). Medicinal Uses of Foeniculum Vulgare Mill and Small Cardamom: A Review, *Journal of Advanced Zoology*, 44(S-3), 1347-1352. <https://doi.org/10.17762/jaz.v44iS-3.1645>
- [22] AlBasher, G., Abdel-Daim, M. M., Almeer, R., Ibrahim, K. A., Hamza, R. Z., Bungau, S., & Aleya, L. (2020). Synergistic antioxidant effects of resveratrol and curcumin against fipronil-triggered oxidative damage in male albino rats. *Environmental Science and Pollution Research*, 27(6), 6505-6514. <https://doi.org/10.1007/s11356-019-07344-8>
- [23] Li, J., Sun, L., Fang, F., & Morshedi, M. (2025). Enhancing Neuroprotection Through Exercise: The Synergistic Effects of Bioactive Plant Compounds Via the CREB-BDNF Signaling Pathway. *Journal of Neuroimmune Pharmacology*, 20(1), 1-17. <https://doi.org/10.1007/s11481-025-10228-z>
- [24] Islam, F., Nafady, M. H., Islam, M. R., Saha, S., Rashid, S., Akter, A., ... & Hussein Sweilam, S. (2022). Resveratrol and neuroprotection: an insight into prospective therapeutic approaches against Alzheimer's disease from bench to bedside. *Molecular Neurobiology*, 59(7), 4384-4404. <https://doi.org/10.1007/s12035-022-02859-7>
- [25] Puranik, N., Kumari, M., Tiwari, S., Dhakal, T., & Song, M. (2025). Resveratrol as a Therapeutic Agent in Alzheimer's Disease: Evidence from Clinical Studies. *Nutrients*, 17(15), 2557. <https://doi.org/10.3390/nu17152557>
- [26] Kadam, P., Shahi, S. (2025), Exploring the Medicinal Properties of Underutilized Zingiberaceae Family Plants: A Comparative Study of Thikur, Ginger, and Turmeric. *International Journal of Environmental Sciences*, 11(4s), 765-777. <https://theaspd.com/index.php/ijes/article/view/627>
- [27] Sanyogita Shahi, Shirish Kumar Singh (2022). Medicinal Plants in Chhattisgarh State, *Journal of Pharmaceutical Negative Reports*, 13(5s), 647-653. <https://doi.org/10.47750/pnr.2022.13.S05.102>
- [28] Zaky, A., Bassiouny, A., Farghaly, M., & El-Sabaa, B. M. (2017). A combination of resveratrol and curcumin is effective against aluminum chloride-induced neuroinflammation in rats. *Journal of Alzheimer's Disease*, 60(s1), S221-S235. <https://doi.org/10.3233/JAD-161111>
- [29] Chinraj, V., & Raman, S. (2022). Neuroprotection by resveratrol: A review on brain delivery strategies for Alzheimer's and Parkinson's disease. *Journal of Applied Pharmaceutical Science*, 12(7), 001-017. <https://doi.org/10.7324/JAPS.2022.120701>
- [30] Shahi, S., Singh, S. K., Dubey, A. (2025) Dopamine-boosting foods: A double-edged sword in heart attack risk through emotional modulation, *Journal of Medicinal and Nanomaterials Chemistry*, 7, 384-407, <https://doi.org/10.48309/jmnc.2025.537683.1116>

-
- [31] Shindikar, A., Singh, A., Nobre, M., & Kirolkar, S. (2016). Curcumin and resveratrol as promising natural remedies with nanomedicine approach for the effective treatment of triple negative breast cancer. *Journal of oncology*, 2016(1), 9750785. <https://doi.org/10.1155/2016/9750785>
- [32] Singh, A., Shahi, S. (2022). Cure of COVID-19 by Turmeric: A Review, *Telematique*, 21 (1), Pages, 3420-3427, ISSN No. 1854-4194, <https://www.provinciajournal.com/index.php/telematique/article/view/436>
- [33] Dubey Anubhav, Shahi Sanyogita, Singh Shirish Kumar, Kumari Mamta and Dwivedi Sumeet (2025), Containers on the micro- and nanoscale for Neurodegenerative diseases: nose-to-brain drug transportation. *Research Journal of Biotechnology*, 28(8), 264-272. 15. <https://doi.org/10.25303/208rjbt2640272>